Hepatitis C Virus Infection in Hemodialysis Patients in the Era of Direct-Acting Antiviral Treatment: Observational Study and Narrative Review
2024

Hepatitis C in Hemodialysis Patients: Study and Review

Sample size: 165 publication 10 minutes Evidence: moderate

Author Information

Author(s): Ratiu Ioana Adela, Mihaescu Adelina, Olariu Nicu, Ratiu Cristian Adrian, Cristian Bako Gabriel, Ratiu Anamaria, Indries Mirela, Fratila Simona, Dejeu Danut, Teusdea Alin, Ganea Mariana, Moisa Corina, Marc Luciana, Harapan Harapan

Primary Institution: University of Oradea

Hypothesis

What are the demographic, clinical, and laboratory characteristics of HCV-positive patients undergoing hemodialysis and the long-term impact of direct-acting antivirals on their outcomes?

Conclusion

HCV infection in hemodialysis patients typically follows a subclinical course, and while liver function stabilizes after DAA therapy, the incidence of malignancies remains high.

Supporting Evidence

  • The incidence of malignancies was significantly higher among HCV-positive compared to HCV-negative patients (20.3% vs. 8.1%, p = 0.023).
  • Laboratory results showed lower serum cholesterol levels in the HCV-positive DAA-treated group compared to non-treated ones.
  • Psychological assessments revealed more severe depression in HCV-positive patients compared to their HCV-negative counterparts.

Takeaway

This study looked at patients on dialysis who have hepatitis C and found that even after treatment, they still have a high chance of getting cancer.

Methodology

A retrospective analysis of 165 hemodialysis patients from Bihor County, Romania, comparing HCV-positive and HCV-negative groups over a period from 2014 to 2024.

Potential Biases

Potential underdiagnosis of HCV due to reliance on immuno-enzymatic methods.

Limitations

The study is retrospective, has a small sample size, and lacks data on liver biopsy and viral load for all patients.

Participant Demographics

The study included 165 hemodialysis patients, with 54 testing positive for HCV and 111 as controls.

Statistical Information

P-Value

p = 0.023 for malignancy incidence comparison

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.3390/medicina60122093

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication